Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Savara Inc. (NASDAQ:SVRA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $7.17.

A number of equities analysts recently weighed in on SVRA shares. Guggenheim reaffirmed a "buy" rating and issued a $8.00 target price (down from $9.00) on shares of Savara in a research note on Wednesday, May 28th. Wells Fargo & Company reduced their target price on shares of Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Wednesday, May 28th. Evercore ISI reduced their target price on shares of Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research note on Wednesday, May 28th. Finally, HC Wainwright lowered shares of Savara from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $6.00 to $2.00 in a research note on Thursday, May 29th.

Savara Price Performance

Shares of SVRA stock opened at $2.28 on Wednesday. Savara has a 12-month low of $1.89 and a 12-month high of $5.11. The firm has a market capitalization of $394.08 million, a price-to-earnings ratio of -4.75 and a beta of 0.32. The company has a quick ratio of 14.91, a current ratio of 14.91 and a debt-to-equity ratio of 0.20. The firm has a fifty day moving average of $2.73 and a 200-day moving average of $2.82.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). On average, equities research analysts forecast that Savara will post -0.45 earnings per share for the current year.

Insider Transactions at Savara

In other Savara news, Director Richard J. Hawkins acquired 48,225 shares of Savara stock in a transaction dated Friday, June 20th. The stock was bought at an average cost of $2.04 per share, for a total transaction of $98,379.00. Following the purchase, the director now directly owns 115,466 shares in the company, valued at approximately $235,550.64. This represents a 71.72% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 5.13% of the company's stock.

Hedge Funds Weigh In On Savara

A number of large investors have recently modified their holdings of the business. Altium Capital Management LLC boosted its stake in shares of Savara by 0.3% during the 4th quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company's stock worth $4,848,000 after buying an additional 4,000 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Savara by 13.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company's stock valued at $135,000 after purchasing an additional 5,236 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Savara by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company's stock valued at $441,000 after purchasing an additional 5,450 shares during the period. Barclays PLC raised its holdings in shares of Savara by 2.5% in the 4th quarter. Barclays PLC now owns 236,705 shares of the company's stock valued at $728,000 after purchasing an additional 5,700 shares during the period. Finally, Farther Finance Advisors LLC raised its holdings in shares of Savara by 25.3% in the 1st quarter. Farther Finance Advisors LLC now owns 32,314 shares of the company's stock valued at $92,000 after purchasing an additional 6,532 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.